What pharmacy benefit designers need to know about perception and reality: Never forget the elephant in the pharmacy

Journal of Managed Care Pharmacy

Volumn 14, Issue 4, 2008, Pages 387-394

  Fairman, Kathleen A ^a  

^a Kathleen Fairman LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIAZEPAM; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OPIATE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; EDITORIAL; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEALTH ECONOMICS; MEDICAL DECISION MAKING; PERCEPTION; SOCIAL BEHAVIOR;

EID: 45949084427     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.4.387     Document Type: Editorial

References (26)

1. U.S. Court of Appeals, Seventh Circuit. Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 03 C 3578. January 3, 2008. Available at: www.ftc.gov/os/caselist/ 0323011/080103qtrayseventhcircuitappealruling.pdf. Accessed April 11, 2008.
2. U.S. District Court for the Northern District of Illinois, Eastern Division. Case No. 03 C 3578. Memorandum Opinion and Order. September 8, 2006. Available at: www.casewatch.org/ftc/enforcements/q-tay/ opinion∠d∨der.pdf. Accessed April 11, 2008.
3. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomized controlled trial in patients with irritable bowel syndrome. BMJ. 2008;April 3 (Epub ahead of print). Available at: www.bmj.com/cgi/reprint/bmj.39524.439618.25vl. Accessed April 11, 2008.
4. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA. 2008;299(9):1016-17.
5. Fairman KA, Curtiss FR. The elephant in the pharmacy: patient choice is the big challenge that no one talks about in affordability of prescription drugs.J Manag Care Pharm. 2007;13(7):620-22. Available at: www.amcp.org/data/jmcp/JMPCPMaga_Sept%2007_620-622.pdf.
6. Chernew M, Fendrick AM. Value and increased cost sharing in the American health care system. Health Serv Res. 2008;43(2):451-57.
7. Seta JJ, Hundt GM, Set CE. Costs' influence on attitudes and value: beyond dissonance theory. Basic Appl Soc Psychol. 1995:17(1&2):267-83.
8. Aronson E, Mills J. The effect of severity of initiation on liking for a group. J Abnorm Soc Psychol. 1959;59:177-81.
9. Seta JJ, Seta CE. Personal equity-comparison theory: an analysis of value and the generation of compensatory and noncompensatory expectancies. Basic Appl Soc Psychol. 1992;13(1):47-66.
10. Greenwald AG, Ronis DL. Twenty years of cognitive dissonance: case study of the evolution of a theory. Psychol Rev. 1978. 85(1):53-57.
11. Doob AN, Carlsmith JM, Freedman JL, Landauer TK, Soleng T. Effect of initial selling price on subsequent sales. J Pers Soc Psychol. 1969;11(4):345-50.
12. Seta JJ, Seta CE, Erber MW. The role of cost in generating expectations and value: a personal equity-comparison theory analysis. Basic Appl Soc Psychol. 1993. 14(1):103-19.
13. Autor DH. Lecture note: market signaling - theory and evidence. Massachusetts Institute of Technology, November 17, 2003. Available at: http://ocw.mit.edu/NR/rdonlyres/Economics/ 14-661Fall-2003-Fall-2004/0EB80652-E538-437C-A303-6044CFBD2A39/0/ lecture_7.pdf. Accessed May 3, 2008.
14. Jones P, Hudson J. Signalling product quality: when is price relevant? J Econ Behav Organ. 1996;30(2):257-66.
15. Milgrom P, Roberts J. Price and advertising signals of product quality. J Polit Econ. 1986;94(4):796-821.
16. Mehegan D. Dan Ariely: learning to ward off those bad decisions. The Boston Globe. March 19, 2008. Available at: www.iht.com/bin/ printfriendly.php?id=11252785. Accessed May 3, 2008.
17. Ariely D. Predictably Irrational: The Hidden Forces That Shape Our Decisions. New York, NY. HarperCollins; 2008.
18. Pavesic D. How to win the menu pricing game. Restaurant Resource Group. Available at: www.rrgconsulting.com/restaurant⋯nu∥icing.htm. Accessed April 14, 2008.
19. Fairman KA. The future of prescription drug cost-sharing: real progress or dropped opportunity? J Manag Care Pharm. 2008;14(1):70-82. Available at: www.amcp.org/data/jmcp/JMCPMaga_JanFeb%2008_070-082.pdf.
20. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-32.
21. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-28.
22. Karter AJ, Parker MM, Moffet HH, et al. Effect of cost-sharing changes on self-monitoring of blood glucose. Am J Manag Care. 2007;13(7):408-16.
23. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff. 2008;27(1):103-12.
24. Fairman YA, Curtiss FR. Making the world safe for evidence-based policy: Let's slay the biases in research on value-based insurance design. J Manag Care Pharm. 2008;14(2):198-204. Available at: www.amcp.org/ data/jmcp/JMCPMaga_March%2008_198-204.pdf.
25. Wang SS. Express Scripts studies how to sway consumers. Wall Street Journal. April 15, 2008:B4.
26. Centers for Medicare & Medicaid Services. National health expenditure projections. Available at: www.cms.hhs.gov/NationalHealthExpendData/ Downloads/proj2007.pdf. Accessed April 21, 2008.